UbiVac adds cancer immunotherapy pioneer Walter Urba to advisory board

By AI, Created 6:08 AM UTC, May 18, 2026, /AGP/ – UbiVac named Walter J. Urba, M.D., Ph.D., to its Scientific Advisory Board as the Portland company pushes its Dark Matter-based immunotherapy platform toward later-stage development. The appointment adds a veteran oncology leader who helped guide UbiVac’s earliest vaccine studies and could support broader clinical and target-discovery work across solid tumors.

Why it matters: - UbiVac is moving its Dark Matter immunotherapy platform toward later-stage development. - Walter J. Urba brings decades of oncology and immunotherapy experience to a company built around off-the-shelf cancer treatments. - Urba’s addition may strengthen UbiVac’s clinical strategy, trial design and target discovery efforts across multiple solid tumors.

What happened: - UbiVac appointed Walter J. Urba, M.D., Ph.D., to its Scientific Advisory Board. - The company announced the move on May 18, 2026. - UbiVac is a Portland, Oregon-based clinical-stage immunotherapy and cancer target discovery company. - Urba previously served as chief medical officer of Providence Cancer Institute. - Urba also founded the Cancer Research Program at the Earle A. Chiles Research Institute.

The details: - Urba helped build one of the nation’s leading immuno-oncology research and clinical trial programs at Providence Cancer Institute and the Earle A. Chiles Research Institute. - His work has included cytokine therapy, cancer vaccines, adoptive cellular therapy and immune checkpoint inhibition. - Bernard A. Fox, UbiVac founder and CEO, said Urba has been deeply involved in the company’s scientific strategy since the earliest development of its vaccine platform. - Fox said Urba served as principal investigator on the first two NCI-funded clinical trials evaluating UbiVac’s technology. - UbiVac’s lead product candidate is DPV-001. - DPV-001 is an off-the-shelf microvesicle-based immunotherapy designed to trigger broad anti-tumor immune responses against shared tumor-associated antigens, including Dark Genome-derived “Dark Matter” antigens. - In a Phase Ib combination study in recurrent/metastatic head and neck squamous cell carcinoma, DPV-001 combination immunotherapy more than doubled overall survival versus historical outcomes for standard-of-care pembrolizumab. - UbiVac’s platform aims at cancer’s “Dark Matter,” which the company describes as non-canonical, non-mutated shared tumor antigens derived from the Dark Genome. - The company says DPV-001 is designed to drive T cell, B cell and innate immune responses against hundreds of tumor-associated antigens across a broad range of solid tumors. - UbiVac says those tumor types include prostate, breast, head and neck, pancreas, lung, ovary, brain, kidney, bladder and colon cancers. - UbiVac is also using immune responses generated against hundreds of Dark Genome-derived antigens to identify future targets for T cell engagers and antibody-drug conjugates. - The company’s social media page is available here.

Between the lines: - The board appointment connects UbiVac’s early scientific roots with its next-stage ambitions. - Urba’s background in translational oncology suggests UbiVac wants closer alignment between discovery work and clinical development. - The focus on non-canonical tumor antigens reflects a broader industry push to expand immunotherapy targets beyond traditional biomarkers and mutations.

What’s next: - UbiVac said it will continue advancing its Dark Matter immunotherapy platform across multiple solid tumor indications. - The company is also using its immune-response data to support future immunotherapy programs and new therapeutic modalities. - Additional clinical and development updates are likely as UbiVac moves DPV-001 and related programs forward.

The bottom line: - UbiVac is betting that Urba’s experience can help turn its unconventional antigen-discovery platform into a broader cancer immunotherapy pipeline.